Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?

Nature Clinical Practice Urology volume 2, pages 80–81 (2005)Cite this article

boxed-textAbratt RP et al. (2004) Randomised phase III study of intravenous vinorelbine plus hormone therapy versus hormone therapy alone in hormone-refractory prostate cancer. Ann Oncol 15: 1613–1621

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Eisenberger MA et al. (1985) A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3: 827–841

    Article  CAS  Google Scholar 

  2. Yagoda A and Petrylak DP (1993) Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 71 (Suppl 3): 1098–1109

    Article  CAS  Google Scholar 

  3. Tannock IF et al. (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14: 1756–1764

    Article  CAS  Google Scholar 

  4. Eisenberger MA et al. (2004) A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). J Clin Oncol 22 (Suppl): abstract 4

    Article  Google Scholar 

  5. Pummer K et al. (1997) Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur Urol 32 (Suppl 3): 81–85

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Suzanne Farley, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor in the Department of Urology, Medical University Graz, Austria

    Karl Pummer

Authors
  1. Karl Pummer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karl Pummer.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pummer, K. Does the addition of vinorelbine to hormone therapy prolong survival of men with hormone-refractory prostate cancer?. Nat Rev Urol 2, 80–81 (2005). https://doi.org/10.1038/ncpuro0089

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0089

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing